OctoRelease’s Commitment to Quality Assurance and Regulatory Compliance

From the earliest stages of development to the final delivery of the drug product, OctoRelease maintains  vigilance over the entire clinical supply chain. With a robust quality assurance (QA) system in place, OctoRelease ensures that all aspects of the supply chain meet the highest regulatory standards.

QA/QP Oversight from Raw Materials to Finished Product

OctoRelease’s commitment to QA/QP oversight extends from the sourcing of drug substance (DS) to the production of the final drug product (FDP). By conducting rigorous audits of all contracted companies involved in the supply chain, OctoRelease verifies adherence to strict quality standards and regulatory requirements.

Formal Agreements to Ensure Clear Responsibilities

In addition to audits, OctoRelease establishes clear and comprehensive agreements with all companies involved in the supply chain. These agreements delineate responsibilities, ensure transparency, and facilitate open communication. The result is a seamless and coordinated approach to QA/QP oversight, ensuring that the highest standards of quality are upheld throughout the entire clinical supply chain.

Partnering with OctoRelease for Assurance and Transparency

OctoRelease’s commitment to QA/QP oversight is a testament to the company’s dedication to providing exceptional service to its clients. By maintaining transparency and ensuring accountability throughout the clinical supply chain, OctoRelease empowers clinical trial sponsors to make informed decisions and prioritize patient safety.

With OctoRelease as your trusted partner, you can rest assured that your clinical trial will benefit from the highest quality standards, regulatory compliance, and a seamless supply chain.